Drug discovery biotech looking into the ‘dark’ regions of the human genome picks up a $40M+ Series A

Date October 19, 2022

While the combo of machine learning and drug discovery has managed to rake in a lot of capital for companies this year, one biotech is …

Read article here

Previous Nucleome secures £37.5M to help illuminate non-coding gene functions Nucleome secures £37.5M to help illuminate non-coding gene functions
October 19, 2022
Next Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines
October 19, 2022